We are thrilled to announce that we have made a strategic Seed investment in Hope AI, a cutting-edge AI-powered clinical development company. Hope AI is transforming the way clinical trials are designed by providing data-driven insights and statistical innovations to clinical teams. Their AI agents facilitate seamless interactions between clinical teams and biostatisticians, enabling faster and more effective decision-making.
Their powerful platform supports faster, evidence-driven insights, enabling the generation of clinical evidence in just six weeks for any new indication, which is just the first part of their offering aimed at speeding up the trial design process. Moving forward, Hope AI can add strategic value by helping implement more adaptive trial designs. The team’s strong track record includes a case study where their AI platform reduced the sample size of a phase 3 trial by 20%, and another where they shortened timelines by up to two years by establishing surrogate endpoints.
Hope AI’s team combines deep expertise in AI, clinical science, statistics, and regulatory affairs, and they are already gaining momentum with industry leaders like BMS and Mayo Clinic.
“Hope AI delivers evidence-driven insights and statistical innovations directly to the fingertips of clinical teams. It was inspiring to see the founder and our biostatistics and clinical development teams find common ground so quickly. With their strong industry experience, the co-founders are exceptionally well-positioned to bring immediate value to Debiopharm programs” – Nicolas Stalder, Senior Investment Associate at Debiopharm Innovation Fund.
“Patients can’t wait. At HopeAI, our mission is to bring hope to patients by accelerating clinical development through artificial intelligence. We have developed AI assistants that combine clinical insights with statistical innovations, enabling faster and more precise clinical trials. Debiopharm isn’t just our investor – they’re our partner in shaping the future for patients.” – Will Ma, CEO and co-founder of HopeAI.